Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

2.11
-0.0700-3.21%
Post-market: 2.10-0.0100-0.47%17:27 EDT
Volume:343.02K
Turnover:723.65K
Market Cap:55.45M
PE:-0.97
High:2.20
Open:2.17
Low:2.07
Close:2.18
52wk High:16.00
52wk Low:2.07
Shares:26.28M
Float Shares:19.19M
Volume Ratio:0.88
T/O Rate:1.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1721
EPS(LYR):-2.5842
ROE:-774.56%
ROA:-77.88%
PB:6.99
PE(LYR):-0.82

Loading ...

Elicio Therapeutics Prices $15 Million Direct Offering

MT Newswires Live
·
Jul 02

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

THOMSON REUTERS
·
Jul 02

Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

GlobeNewswire
·
Jun 29

Elicio Therapeutics Posts Amplify-7p Presentation on Eli-002 7P in Metastatic Mkras Pancreatic Cancer

Reuters
·
Jun 25

Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 22

Elicio Therapeutics Coverage Assumed by Ladenburg Thalmann at Buy

Dow Jones
·
Jun 19

Elicio Therapeutics assumed with a Buy at Ladenburg

TIPRANKS
·
Jun 18

Top Premarket Decliners

MT Newswires Live
·
Jun 18

Elicio Reports Complete Responses in 3 Pancreatic Cancer Patients After ELI-002 7P, Nivolumab Treatment

MT Newswires Live
·
Jun 17

Elicio Therapeutics reports complete responses in pancreatic cancer trial

TIPRANKS
·
Jun 17

Elicio Therapeutics plans Phase 1 trial of ELI-002 7P plus anti-PD-1, chemo in metastatic mKRAS pancreatic cancer

Reuters
·
Jun 17

Elicio Therapeutics - Complete Responses Observed in Mss/Mmr-P Patients With Historically Checkpoint Inhibitor Response

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics - Reports 100% Confirmed Complete Responses in Three Patients After Eli-2 7P and Nivolumab

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics - Two Patients Maintain Complete Responses for at Least Eight Months, One Over 13 Months

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics - Plans to Initiate Phase 1 Study in Metastatic Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS
·
Jun 17

Elicio Therapeutics Reports Multiple Complete Responses After Eli-002 7P Treatment and Subsequent Therapy With Checkpoint Inhibition in Metastatic Mkras Pancreatic Cancer

THOMSON REUTERS
·
Jun 17

SueWallSt opens probe into Elicio Therapeutics officers, directors after 72.53% stock plunge

Reuters
·
Jun 17

Elicio Therapeutics Cut to Hold From Buy by Jones Trading

Dow Jones
·
Jun 17

Elicio Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Jun 16